SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending despite beating earnings estimates and raising guidance, as investors debate whether its valuation is justified amid high P/E ratios and concerns of an AI bubble. Community chatter also mentions Michael Burry's bearish stance, with some retail traders rallying against his position and others expressing caution. Discussions include the company's future growth potential, government contracts, and overall market sentiment.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as community members discuss its potential AI integrations and undervalued status relative to other cryptocurrencies. Some believe ICP is poised for a significant breakout, citing its technology and potential to disrupt the cloud computing market, while others remain skeptical based on its price history. Bullish sentiment is fueled by discussions around staking rewards and increasing network usage.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto token $CAW (crow with knife) is trending as the community rallies around its multi-chain presence ($SOL, $CRO, $ETH) and deflationary mechanisms. Community members frequently mention "caw caw" and various partnerships, while also using the token's ticker as a rallying cry alongside other meme tokens like $SLAP, $RAGE, and $WAGMI.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about its recent earnings and the impact of COVID-era data on trial results for PMO therapies; while some express concern over missed statistical significance, others highlight the revenue beat and potential for Elevidys to replace older treatments. The community is debating the likelihood of FDA action on PMO drugs and the company's overall valuation in light of recent events, with some suggesting a buyout opportunity.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending amid a broader crypto selloff, with the community debating potential bottom prices and the influence of external factors like government shutdowns and the TradFi market. Traders are closely watching technical indicators, while some express frustration with price predictions from crypto analysts. Liquidations and market manipulation remain key concerns.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending, with community members highlighting staking opportunities and a dedicated team. There's a strong sense of community, focusing on the project's meme culture and real-world partnerships. Bulls express confidence in SLAP's potential, while some caution against the hype.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to a post-earnings selloff, with the community debating whether the drop is an overreaction or a sign of deeper issues related to AI spending and future profitability. Sentiment is mixed, ranging from calls to buy the dip to concerns about technicals and potential further declines. Some traders are pointing to historical patterns and oversold conditions as potential catalysts for a bounce.

eToro Group Ltd. engages in the development, management, and provision of online trading software solutions and services. The firm's trading platform, eToro, allows users to trade financial instruments. It also enables non-professionals to trade in markets that were previously the exclusive arena of professional investors. The company was founded by Johnathan Alexander Assia, Guy Gamzu, David Ring, and Ronen Assia on December 14, 2006 and is headquartered in Bnei Braq, Israel.

Etoro Group Ltd - Ordinary Shares - Class A

eToro Group Ltd

eToro Group $ETOR is trending as investors digest recent analyst ratings, with community chatter focused on price target speculation and overall valuation compared to peers like Robinhood. Some traders are also closely watching the lock-up period, while others highlight the stock's sensitivity to geopolitical events given its Israeli roots. There is also discussion around LEAPS options and possible benefits from broader fintech trends.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending amid mixed sentiment heading into earnings, with discussions around a potential deal with Novo Nordisk for weight-loss drugs like Wegovy. The community is closely watching subscriber growth and margin expansion, while analysts debate the impact of increased competition and past concerns regarding GLP-1s. Some traders are betting on a post-earnings squeeze, while others point to technical indicators suggesting further downside.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid concerns of an AI bubble burst and potential market correction, fueled by overnight futures drops. Community chatter highlights skepticism towards the sustainability of the tech-led rally, with some bracing for a significant pullback. Traders are closely watching key support levels and debating whether this is a buying opportunity or the start of a deeper downturn.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.

ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering

Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.

Shares of Esperion Therapeutics tumbled almost 20% in premarket trading on Wednesday after the cholesterol drugmaker moved to raise fresh capital through a steeply discounted stock sale.The company priced its new offering at $2.50 per share, about 19% below Tuesday’s closing price of $3.09. Esperion expects to raise roughly $75 million from the sale of 30 million shares, with an option for underwriters to buy an additional 4.5 million shares over the next month. The deal is expected to close around Oct. 9.Meanwhile, Morgan Stanley, Piper Sandler, and Cantor Fitzgerald are leading the offering, joined by Citizens JMP Securities, H.C. Wainwright, and Needham &amp; Company as co-managers. Esperion said the proceeds will go toward expanding commercialization of its non-statin cholesterol treatments and strengthening its financial position.The fundraising effort comes after the Michigan-based biotech firm notched a legal win protecting its core cholesterol-lowering drugs. Last week,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion reached a settlement with Dr. Reddy’s Laboratories</a>, ensuring the Indian pharma company cannot market generic versions of Nexletol and Nexlizet in the U.S. before April 19, 2040.That settlement followed similar agreements with Micro Labs USA, Hetero USA, and Accord Healthcare, effectively shoring up Esperion’s patent on bempedoic acid, the key ingredient in both drugs, through December 2030.On Stocktwits, retail sentiment for Esperion was ‘bullish’ amid ‘high’ message volume.One retail trader said the real question now is whether Esperion will use the new funds wisely, whether to repay debt and support its late-stage trials, rather than chase new acquisitions or side projects, which could signal poor capital discipline.<stembedurl>https://stocktwits.com/Sirius1026/message/631430171</stembedurl>Another user speculated that the timing of the offering hinted at deeper management motives, suggesting the cash crunch might be over and predicting a quick rebound above $3.<stembedurl>https://stocktwits.com/Rescueoncredit/message/631430163</stembedurl><a href="https://stocktwits.com/symbol/ESPR">Esperion’s stock</a> has risen 40.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is Esperion Therapeutics Stock Sinking Premarket Today?

The stock fell sharply in early trade after the cholesterol drugmaker priced its latest stock sale at a discount to Tuesday’s close.

Equity

ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up

Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.

Esperion (ESPR) on Friday said that it has entered into a settlement agreement with Dr. Reddy’s Laboratories and its affiliate under which the latter has agreed not to market a generic version of either Nexletol or Nexlizet in the United States before April 19, 2040.The agreement <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/03/3160929/0/en/Esperion-Reaches-Settlement-Agreement-with-ANDA-Filer-Dr-Reddy-s-Laboratories-Not-to-Market-Generic-Versions-of-NEXLETOL-bempedoic-acid-and-NEXLIZET-bempedoic-acid-and-ezetimibe-Pr.html">resolves</a> the patent litigation brought by Esperion against Dr. Reddy’s Laboratories after it submitted an Abbreviated New Drug Application seeking approval to market a generic version of each of Nexletol and Nexlizet.The two drugs are used to reduce low-density lipoprotein (LDL) or "bad" cholesterol in adults with high blood cholesterol levels, known as primary hyperlipidemia. Shares of Esperion traded 8% higher in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ESPR">ESPR stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.Esperion reached a settlement agreement with Micro Labs USA and its affiliate; Hetero USA, and its affiliates; and Accord Healthcare earlier this year with respect to their generic versions of Nexletol.The bempedoic acid portion of the two drugs is claimed in an Esperion patent scheduled to expire in December 2030, the company said. With the settlement with Dr. Reddy’s, there are no remaining challenges regarding the validity or infringement of the said patent in the pending patent litigation, it added.The company also stated that there is no assurance that the ongoing patent litigation against the remaining defendants, including Alkem Laboratories, will allow a generic version of the cholesterol drugs to be marketed in the U.S. before April 19, 2040.ESPR stock is up by 32% this year and by approximately 48% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ovid-therapeutics-stock-rally-pre-market-after-positive-results-from-trial-of-potential-seizure-treatment/chCuj8HR3Q2">Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs

The company said that Dr. Reddy’s Laboratories has agreed not to market a generic version of either Nexletol or Nexlizet in the U.S. before April 19, 2040. 

Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?

Investors need to pay close attention to Esperion Therapeutics stock based on the movements in the options market lately.

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of +88.24% and +24.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion Therapeutics Inc.

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ESPR News

ESPREsperion Therapeutics Inc.